Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19

Although remdesivir, a prodrug of nucleoside analog (GS‐441524), has demonstrated clinical benefits in coronavirus disease 2019 (COVID‐19) treatment, its pharmacokinetics (PKs) in patients with COVID‐19 remain poorly understood. Therefore, in this study, the PKs of remdesivir and its major metabolit...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Ryo, Irie, Kei, Nakagawa, Atsushi, Muroi, Hirohito, Eto, Masaaki, Ikesue, Hiroaki, Muroi, Nobuyuki, Fukushima, Shoji, Tomii, Keisuke, Hashida, Tohru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088080/
https://www.ncbi.nlm.nih.gov/pubmed/36798006
http://dx.doi.org/10.1002/psp4.12936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088080/
https://www.ncbi.nlm.nih.gov/pubmed/36798006
http://dx.doi.org/10.1002/psp4.12936

Ejemplares similares